AXT Hits New Highs on Q1 Strength, But Extreme Valuation and Permit Risks Loom

What happened

AXT reported strong Q1-2026 results driven by Indium Phosphide demand, pushing the stock to new all-time highs. The company plans to double InP capacity over two years, but the stock's 7,000% gain over the past year has pushed valuation to extreme levels. Despite the upbeat headline, DeepValue analysis reveals FY2025 revenue fell 11% to $88.3M, gross margin compressed to 12.7%, and net loss widened to $23.2M. The binding constraint remains China export-permit uncertainty, with the 10-K stating timing is 'uncertain and beyond our control,' and the April 2026 equity offering ($550M-$632.5M gross) adds dilution risk. Insider selling in March 2026, including CFO Fischer unloading 405k shares, further signals caution amid a narrative-driven rally.

Implication

Long-term holders should require two clean quarters of permit-driven shipment growth and margin recovery above 20% before adding. The current risk/reward is unfavorable with a bear case target of $40.

Thesis delta

The narrative has shifted from 'permits as catalyst' to 'funded capacity expansion,' but the underlying risk remains: permits are still uncertain, and the massive equity raise dilutes existing holders without guaranteeing faster revenue conversion. Until Q2 2026 results show smoother shipments and margin improvement, the stock's 7,000% rally is disconnected from fundamental reality.